Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chlamydia pneumoniae and atherosclerosis.

J D Rutherford1

  • 1Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390-9047, USA. jruthe@mednet.swmed.edu

Current Atherosclerosis Reports
|December 21, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Peripartum cardiomyopathy.

The New England journal of medicine·2001
Same author

Diabetes and coronary artery disease--therapy and outcomes.

Coronary artery disease·2001
Same author

Association between C-reactive protein, anti-Chlamydia pneumoniae antibodies, and vascular function in healthy adults.

The American journal of cardiology·2001
Same author

Systolic hypertension in older patients: are calcium channel antagonists safe?

Coronary artery disease·2000
Same author

The clinical dilemma of anorectic drug use and valvular heart disease.

The American journal of cardiology·1999
Same author

Place conditioning with the dopamine D1-like receptor agonist SKF 82958 but not SKF 81297 or SKF 77434.

European journal of pharmacology·1998

Chlamydia pneumoniae infection is linked to atherosclerosis by promoting inflammation and foam cell formation in arteries. Antibiotic therapy may reduce cardiovascular events by targeting this pathogen.

Area of Science:

  • Cardiovascular Research
  • Infectious Diseases
  • Pathogen-Host Interactions

Background:

  • Chlamydia pneumoniae is a common respiratory pathogen frequently detected in atherosclerotic arteries.
  • Experimental evidence shows C. pneumoniae infects key vascular cells, including macrophages, endothelial cells, and smooth muscle cells.
  • C. pneumoniae infection is implicated in the dysregulation of low-density lipoprotein (LDL) metabolism, contributing to foam cell formation.

Purpose of the Study:

  • To explore the role of Chlamydia pneumoniae in atherogenesis.
  • To summarize evidence linking C. pneumoniae infection to cardiovascular disease.
  • To review potential therapeutic strategies targeting C. pneumoniae in cardiovascular disease.

Main Methods:

  • Review of existing literature on C. pneumoniae presence in arteries.

Related Experiment Videos

  • Analysis of experimental studies on C. pneumoniae's cellular mechanisms.
  • Evaluation of findings from secondary prevention studies involving antibiotic therapy.

    • Main Results:

    • C. pneumoniae is consistently found in human atherosclerotic lesions.
    • In vitro studies demonstrate C. pneumoniae's ability to induce foam cell formation in macrophages.
    • Epidemiological and clinical studies suggest a correlation between C. pneumoniae infection and cardiovascular events.

    Conclusions:

    • Chlamydia pneumoniae may contribute to atherosclerosis by inducing vascular inflammation and immune responses.
    • Targeting C. pneumoniae with antibiotics could be a potential strategy for secondary prevention of cardiovascular events.
    • Further research is warranted to elucidate the precise mechanisms and clinical utility of anti-chlamydial therapies in cardiovascular disease.